期刊文献+

肾复汤对慢性肾炎患者血清氧化低密度脂蛋白的影响 被引量:3

The Influence of Kidney-Recovery Decoction on Serum Oxidized Low Density Lipoprotein of Patients with Chronic Nephritis
下载PDF
导出
摘要 目的:观察肾复汤对痰瘀互结型慢性肾炎伴高脂血症患者血清氧化低密度脂蛋白的影响。方法:选择痰瘀互结型慢性肾炎伴高脂血症患者60例,随机分为治疗组和对照组各30例。对照组给予西药对症治疗,治疗组在对照组的治疗基础上给予肾复汤治疗。结果:治疗后治疗组氧化低密度脂蛋白水平、中医证候积分改善情况均优于对照组(P均<0.01);治疗后治疗组24小时尿蛋白定量优于对照组(P<0.01);与同组治疗前比较,治疗组TG、TC水平有显著性降低(P<0.01)。结论:肾复汤具有降低痰瘀互结型慢性肾炎伴高脂血症患者血清氧化低密度脂蛋白、尿蛋白定量、血脂水平的作用,血清氧化低密度脂蛋白与蛋白尿水平有高度正相关性。 Objective:Tn observe the influence of Kidney - Recovery Decoction on patients with chronic nephritis due to phlegm and blood stasis syndrome,combined with hyperlipidemia. Methods:60 patients with chronic nephritis due to phlegm and blond stasis syndrome,combined with hyperlipidemia,were randomly divided into tile treatment group and the control group, with 30 cases in each group. The patients in the control group were given symptomatic western medicine treatment, while the ones in the treatment group were added Kidney - Recovery+ Decoction on the basis t^atment of the control group. Results : In terms of oxidized low density lipopmtein level and TCM syndrome integral improvement, after the treatment, the treatment group was better than those of the control group( both P 〈 0.01 ) ;In terms of 24h urine protein fixed quantity,the treatment group was better than that of the control group( both P〈 0.01 ) ;In terms of TG and TC, they were greatly reduced after the treatment within the same treatment group( P 〈 0.01 ). Conclusion : Kidney - Recovery Decoction can reduce serum oxidized low density lipoprotein, urine protein fixed quantity and blood fat level of patients with chronic nephritis due to phlegm and blood stasis syndrome. There is a highly positive correlation between serum oxidized low density lipoprotein and urine protein level.
出处 《河南中医》 2014年第12期2354-2356,共3页 Henan Traditional Chinese Medicine
基金 福建省卫生厅中医科研重点课题(编号:wzzsb0910)
关键词 慢性肾炎 肾复汤 痰瘀互结证 氧化低密度脂蛋白 24小时尿蛋白定量 chronie nephritis Kidney - Recovel7 Decoction phlegm and blond stasis syndrome oxidized low density lipoprotein 24h urine protein fixed quantity
  • 相关文献

参考文献9

  • 1Tolins JP,shooe BG,Raij L.Lnteractions.of hyperchvles-olemia and hypertension in imitiation of glomenlhur iujury[J].Kidney lnt,1992,41(5):1254-1261.
  • 2Takahashi M,Arita Y,Yamagata K,et al,Genomic structure and mutations in adipose specific gene adiponectin[J].Int J Obes Relat Metab Disord,2000,24(7):861-868.
  • 3Lee HS,Song CY.Oxidized lowdensity lipoprotein and oxidat ivestress in the development of glomeru loscleros[J].Am JN eph ro,2009,29:62-70.
  • 4Bickel C,Rupprecht HJ,Blankenberg S,et al.Relation of markers of inflammation(C-reactive protein,fibrinogen,von Willebrandfactor,and leukocyte count)and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease[J].Am JCardiol,2002,89(8):901.
  • 5Talwar S,Squire IB,Downie PF,et al.Plasma N terminal probrain natriuretic peptide and cardiotrophin1 are raised in unstable angina[J].Heart,2000,84(4):421.
  • 6Krishnaswamy P,Lubien E,Clopton P,et al.Utitlity of Bnatriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction[J].Am J Med,2001,111(4):274.
  • 7胡昊,李凤,丁晓梅.血浆脑钠肽在急性冠脉综合征患者的变化及与冠脉病变范围的关系[J].中国心血管病研究,2008,6(8):591-593. 被引量:22
  • 8刘智勇,杨永淑,等.血浆NO、ET、OX—LDL水平变化与糖尿病肾病的早期诊断[J].中国检验医学与临床,2000,1(4):180-181. 被引量:3
  • 9刘智勇,袁兴红,杨永淑.不同期糖尿病肾病血浆一氧化氮、内皮素、氧化低密度脂蛋白水平变化[J].中华内分泌代谢杂志,2001,17(5):305-305. 被引量:13

二级参考文献9

  • 1[1]James SK,Lindahl B,Siegbahn A,et al.N-terminal probrain natriuretic peptide and other risk factors for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease.A global utilization of strategies to open occluded arteries(GUSTO)Ⅳ substudy.Circulation,2003,108:275-281.
  • 2[2]Iwanaga Y,Nishi I,Furuichi S,et al.B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure:Comparison between systolic and diastolic heart failure.J Am Coll Cardiol,2006,47:742-748.
  • 3[3]Suzuki T,Yamazaki T,Yazaki Y,et al.The role of the natriuretic peptide in the cardiovascular system.Cardiovasc Res,2001,51:489-494.
  • 4[4]Asada J,Tsuji H,Iwasaka T,et al.Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine induced myocardial ischemia.Am J Cardiol,2004,93:702-704.
  • 5[5]Hopkins WE,Chen Z,Fukagawa NK,et al.Increased atrial and brain natriuretic peptide in adults with cyanotic congenital heart disease.Circulation,2004,109:2872-2877.
  • 6[8]Morita E,Yasue H,Yoshimura M,et al.Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction.Circulation,1993,88:82-91.
  • 7[9]Aylin Y,Sadik A,Cagatay E,et al.Effects of lesion complexity on baseline and postprocedural B-type nstriuretic peptide levels in patients undergoing percutaneous coronary interventions.Tex Heart Inst J,2007,34:282-289.
  • 8Lgnarro LJ,Buga GM,Wood KS,et al.Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide[].Proceedings of the National Academy of Sciences of the United States of America.1997
  • 9Benigni A,Colsiol V,Brena C,et al.Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes[].Diabetes.1998

共引文献35

同被引文献54

  • 1王琳,陈以平.陈以平教授“微观辨证”学术思想在膜性肾病中的应用[J].上海中医药大学学报,2006,20(3):29-31. 被引量:65
  • 2石刚,刘婷.冠心病及其常见中医证型与超敏C反应蛋白的关系探讨[J].中医药临床杂志,2007,19(1):29-30. 被引量:15
  • 3李贵.小儿肺虚证、脾虚证、血瘀证及肾虚证诊断标准[J].中国中西医结合杂志,2007,27(6):568-568. 被引量:36
  • 4武明虎,弓复生.黄芪理肾汤治疗慢性肾炎 45 例[J].中医药研究,1997,13(2):37-38. 被引量:1
  • 5Jia H,Jezequel S,Lohr M, et al. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological response and angiogenesis induced by VEGF[J]. Biochem Biophys Res Commun, 2001,283 ( 1 ) : 164-173.
  • 6Olofsson B,Pajusola K,von Euler G,et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform[J]. J Biol Chem, 1996,271(32): 19310-19317.
  • 7Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4 (VEGFR- 3) and KDR(VEGFR-2) receptor tyrosine kinases[J]. EMBO J, 1996,15(7) : 1751.
  • 8Hoshi S,Nomoto K,Kuromitsu J, et al. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes[J] Biochemi Biophys Res Commun,2002,290(1) : 177-184.
  • 9Tsuzuki Y,Fukumura D, Oosthuyse B,et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-lalpha-->hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors[J]. Cancer Res,2000, 60(22) : 6248-6252.
  • 10Yamaqishi S,Inaqaki Y,Okamoto T,et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cuhured mesangial cells[J]. J Biol Chem, 2002,277 (23) : 20309-20315.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部